Cost-Effectiveness of Zoledronic Acid in the Management of Skeletal Metastases in Patients With Lung Cancer in France, Germany, Portugal, The Netherlands, and the United Kingdom

Clinical Therapeutics

Volumn 33, Issue 3, 2011, Pages

  Joshi, Avani D ^a,b   Carter, John A ^a   Botteman, Marc F ^a   Kaura, Satyin ^c  

^a PHARMERIT INTERNATIONAL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bone metastases; Cost effectiveness; Lung cancer; Zoledronic acid

Indexed keywords

ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; CANCER CENTER; CANCER INCIDENCE; CANCER PATIENT; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; FRANCE; GERMANY; HEALTH CARE; HUMAN; INTERNET; LUNG NON SMALL CELL CANCER; NETHERLANDS; PHASE 3 CLINICAL TRIAL; PORTUGAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SPINAL CORD COMPRESSION; UNITED KINGDOM; UNIVARIATE ANALYSIS; VERTEBRA FRACTURE;

EID: 79955990618     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.04.002     Document Type: Article

References (32)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Cersosimo R.J. Lung cancer: a review. Am J Health Syst Pharm 2002, 59:611-642.
3. Stinchcombe T.E., Lee C.B., Socinski M.A. Current approaches to advanced-stage non-small-cell lung cancer: first-line therapy in patients with a good functional status. Clin Lung Cancer 2006, 7(Suppl 4):S111-S117.
4. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27:165-176.
5. Zarogoulidis K., Boutsikou E., Zarogoulidis P., et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 2009, 125:1705-1709.
6. Coleman R. Management of bone metastases. Cancer Treat Rev 1997, 23(Suppl 1):S69-S75.
7. Delea T., Langer C., McKiernan J., et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004, 67:390-396.
8. Hillner B.E., McDonald M.K., Desch C.E., et al. Costs of care associated with non-small-cell lung cancer in a commercially insured cohort. J Clin Oncol 1998, 16:1420-1424.
9. Schulman K.L., Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer 2007, 109:2334-2342.
10. Aapro M., Abrahamsson P.A., Body J.J., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008, 19:420-432.
11. Rosen L.S., Gordon D., Tchekmedyian S., et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003, 21:3150-3157.
12. Rosen L.S., Gordon D., Tchekmedyian N.S., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004, 100:2613-2621.
13. Hillner B.E., Weeks J.C., Desch C.E., Smith T.J. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000, 18:72-79.
14. Groot M.T., Boeken Kruger C.G., Pelger R.C., Uyl-de Groot C.A. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol 2003, 43:226-232.
15. Groot M.T., Huijgens P.C., Wijermans P.J., Uyl-de Groot C.A. Cost of multiple myeloma and associated skeletal-related events in The Netherlands. Expert Rev Pharmacoecon Outcomes Res 2004, 4:565-572.
16. Felix J, Andreozzi V, Soares M, et al. Treatment costs of skeletal related events in patients with metastatic breast or prostate cancer. Presented at: 14th European Cancer Conference (ECCO 14); September 23-27, 2007; Barcelona, Spain.
17. McKean H., Miller R.C., Jatoi A. Non-traumatic vertebral fractures in patients with locally advanced esophageal cancer: a previously unreported, unrecognized problem. Dis Esophagus 2007, 20:102-106.
18. Ross P.D., Davis J.W., Epstein R.S., Wasnich R.D. Pain and disability associated with new vertebral fractures and other spinal conditions. J Clin Epidemiol 1994, 47:231-239.
19. DesHarnais Castel L., Bajwa K., Markle J.P., et al. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer 2001, 9:545-551.
20. Doyle S., Lloyd A., Walker M. Health state utility scores in advanced non-small cell lung cancer. Lung Cancer 2008, 62:374-380.
21. Botteman M., Barghout V., Stephens J., et al. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 2006, 17:1072-1082.
22. Franic D.M. Cost-utility analysis. Pharmacoeconomics and Outcomes: Applications for Patient Care, Case Studies 2003, 146-181. American College of Clinical Pharmacy, Kansas City. D.W. Grauer, J. Lee, T.D. Odom (Eds.).
23. Nafees B., Stafford M., Gavriel S., et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 2008, 6:84.
24. Berthelot J.M., Will B.P., Evans W.K., et al. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. J Natl Cancer Inst 2000, 92:1321-1329.
25. Cella D., Li J.Z., Cappelleri J.C., et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol 2008, 26:3763-3769.
26. Dranitsaris G., Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support Care Cancer 1999, 7:271-279.
27. van den Hout W.B., van der Linden Y.M., Steenland E., et al. Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst 2003, 95:222-229.
28. Mahtani R., Jahanzeb M. Bisphosphonates as anticancer therapy for early breast cancer. Clin Breast Cancer 2010, 10:359-366.
29. Schlander M. Measures of efficiency in healthcare: QALMs about QALYs?. Z Evid Fortbild Qual Gesundhwes 2010, 104:214-226.
30. Durand-Zaleski I. Economic evaluation of radiotherapy: methods and results [in French]. Cancer Radiother 2005, 9:449-451.
31. Ross J.R., Saunders Y., Edmonds P.M., et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess 2004, 8:1-176.
32. Curtis L. Unit Costs of Health and Social Care 2007 2007, Personal Social Services Research Unit, University of Kent, Canterbury, Kent, United Kingdom.